The NI‐WB results showed that the activation states of MAPK and PI3K/Akt is relatively lower in most CRC primary tumors (Fig. 1A,B, Fig. S1 and Fig. 2A,B, Fig. S2), regardless of KRAS oncogenic mutation status. The gene discussed is KRAS; the disease is colorectal carcinoma.